2019
DOI: 10.1016/j.urology.2018.07.064
|View full text |Cite
|
Sign up to set email alerts
|

Testosterone Therapy for High-risk Prostate Cancer Survivors: A Systematic Review and Meta-analysis

Abstract: word count: 100Manuscript text word count: 3763 Abstract A systematic review and meta-analysis was performed to determine the relationship between testosterone therapy and risk of recurrence in testosterone-deficient survivors of curatively treated high-risk prostate cancer. Primary outcome was the risk of biochemical recurrence (BCR) in 109 high-risk patients in 13 included studies . Biochemical and symptomatic effects of therapy were also reviewed. The BCR rate was 0.00 (0.00-0.05), lower than the expected r… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
12
0

Year Published

2020
2020
2022
2022

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 15 publications
(12 citation statements)
references
References 45 publications
0
12
0
Order By: Relevance
“…However, increased short‐term (mostly < 12 months, maximum three years) risk of incident prostate cancer, prostate‐related adverse events, increase in LUTS or prostate volume or breast cancer have not been documented following TRT in men with low T . TRT in men with treated prostate cancer remains controversial, with only scarce evidence to support its safety . Information on the use of TRT in men with breast cancer following curative treatment is not available …”
Section: Safety and Contraindicationsmentioning
confidence: 99%
“…However, increased short‐term (mostly < 12 months, maximum three years) risk of incident prostate cancer, prostate‐related adverse events, increase in LUTS or prostate volume or breast cancer have not been documented following TRT in men with low T . TRT in men with treated prostate cancer remains controversial, with only scarce evidence to support its safety . Information on the use of TRT in men with breast cancer following curative treatment is not available …”
Section: Safety and Contraindicationsmentioning
confidence: 99%
“…The authors strongly cautioned against over interpretation, seeing that the available body of evidence was of very low quality. 52 Another meta-analysis sought to evaluate the association between TRT in nonmetastatic PCa patients after definitive local therapy and the rate of BCR. Twenty-one studies were included with an overall pooled BCR rate of 0.01 (95% CI 0.00 À 0.02), suggesting a lack of association between TRT and BCR.…”
Section: Trt In Patients With Treated Pcamentioning
confidence: 99%
“…According to recent advances in the current understanding of how TRT might affect PCa biology, T therapy might be considered in highly symptomatic men with LOH even in the presence of advanced or high‐risk disease 57. The limited evidence currently available suggests that, for those with PCa and symptoms of LOH, TRT might be feasible without a significant increase in the risk of cancer progression.…”
Section: Testosterone In Pcamentioning
confidence: 99%
“…16 However, more recent scientific evidence has challenged this basic assumption, and more ongoing studies have been changing the understanding of how TRT might impact men with PCa. 23,[53][54][55][56][57] There are also studies suggesting men with higher endogenous T levels are not at a higher risk of developing PCa. 58,59 A meta-analysis of prospective cohort studies has found no link between endogenous androgen levels and the risk of developing prostate cancer.…”
Section: Te S Tos Terone In P C a T Is Intrinsically Involved In Thmentioning
confidence: 99%
See 1 more Smart Citation